Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a open-label single-arm study of TCN-202 for cytomegalovirus prophylaxis after kidney transplant
RBR-8gcx9mPhase 2Recruiting
- Sponsor
- Theraclone Sciences
- Start
- Aug 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of TCN-202 in cytomegalovirus disease (CMV), sponsored by Theraclone Sciences. Started Aug 2013; status: recruiting.
02
Drugs
TCN-202
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on RBR-8gcx9m.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-8gcx9m.